Trial Profile

An open-label study to investigate the safety and pharmacokinetics of multiple ascending doses of antisense oligonucleotide STK-001 in children and adolescents with Dravet syndrome

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 12 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Zorevunersen (Primary)
Indications Dravet syndrome
Focus Adverse reactions; Pharmacokinetics
Acronyms ADMIRAL; STK-001-DS-102 (ADMIRAL)
Sponsors Stoke Therapeutics

Most Recent Events

04 Mar 2026 According to a Biogen media release, data from the trial were presented in The New England Journal of Medicine (NEJM).
04 Mar 2026 Results presented in the Biogen Media Release
05 Dec 2025 According to the Stoke Therapeutics media release, data from this trial were presented at the 2025 American Epilepsy Society (AES) Annual Meeting in Atlanta, Georgia.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com